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pithelial tight junctions regulate paracellular permeabil-
ity, restrict apical/basolateral intramembrane diffusion of
lipids, and have been proposed to participate in the
control of epithelial cell proliferation and differentiation.
Previously, we have identiﬁed ZO-1–associated nucleic
acid binding proteins (ZONAB), a Y-box transcription factor
whose nuclear localization and transcriptional activity is
regulated by the tight junction–associated candidate tu-
mor suppressor ZO-1. Now, we found that reduction of
ZONAB expression using an antisense approach or by
RNA interference strongly reduced proliferation of MDCK
cells. Transfection of wild-type or ZONAB-binding fragments
of ZO-1 reduced proliferation as well as nuclear ZONAB
E
 
pools, indicating that promotion of proliferation by
ZONAB requires its nuclear accumulation. Overexpression
of ZONAB resulted in increased cell density in mature
monolayers, and depletion of ZONAB or overexpression of
ZO-1 reduced cell density. ZONAB was found to associate
with cell division kinase (CDK) 4, and reduction of nuclear
ZONAB levels resulted in reduced nuclear CDK4. Thus, our
data indicate that tight junctions can regulate epithelial cell
proliferation and cell density via a ZONAB/ZO-1–based
pathway. Although this regulatory process may also involve
regulation of transcription by ZONAB, our data suggest that
one mechanism by which ZONAB and ZO-1 inﬂuence prolif-
eration is by regulating the nuclear accumulation of CDK4.
 
Introduction
 
Epithelial cells interact with each other via specialized inter-
cellular junctions that are critical for the development and
function of epithelial tissues. Tight junctions are the most
apical intercellular junction, and form a morphological border
between the apical and basolateral cell surface domains
(Farquhar and Palade, 1963). They regulate paracellular perme-
ability  and prevent intermixing of apical and basolateral
membrane components (Cereijido et al., 1998). Tight junc-
tions have also been proposed to function in the regulation of
epithelial cell proliferation and differentiation; however, the
involved components and affected signaling pathways are not
well understood (Mitic and Anderson, 1998; Stevenson and
Keon, 1998; Tsukita et al., 1999; Benais-Pont et al., 2001).
Tight junctions are composed of different types of membrane
proteins that mediate cell–cell adhesion and form the diffusion
barriers. The membrane proteins interact with a complex of
cytoplasmic plaque that contains different types of proteins
and is linked to the actin cytoskeleton (Cereijido et al.,
2000; Gonzalez-Mariscal et al., 2000; Zahraoui et al., 2000;
Fanning, 2001; Tsukita et al., 2001; D’Atri and Citi, 2002).
ZO-1, one of these tight junction-associated cytosolic proteins,
is a member of the membrane-associated guanylate kinases
(MAGUK) family of proteins, which possess several PDZ
domains, one SH3 domain, and a domain homologous to
yeast guanylate kinase (Stevenson et al., 1986; Itoh et al.,
1993; Willott et al., 1993; Woods and Bryant, 1993). Although
ZO-1 specifically associates with tight junctions in epithelial
cells (Stevenson et al., 1986), the protein has been reported
to appear in the nucleus during proliferation (Gottardi et al.,
1996). ZO-1 is down-regulated in breast cancer tissues and
during corneal wound repair, suggesting that expression levels
of ZO-1 are related to the proliferation state of epithelial cells
(Hoover et al., 1998; Cao et al., 2002). This is also supported
by the observations that ZO-1 becomes stabilized in confluent
MDCK cells and that its expression levels increase with cell
density (Gumbiner et al., 1991; Balda and Matter, 2000).
We recently identified ZO-1–associated nucleic acid
binding protein (ZONAB),* a Y-box transcription factor
that specifically binds to the SH3 domain of ZO-1 and
regulates the expression of the proto-oncogene erbB-2 in a
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cell density–dependent manner (Balda and Matter, 2000).
ZO-1 functions as an inhibitor of ZONAB and controls ac-
cumulation of ZONAB in the nucleus by cytoplasmic se-
questration. MDCK epithelial cells express two isoforms of
ZONAB (ZONAB-A and -B) that differ in a 68-amino acid
insertion. Both isoforms bind to ZO-1 and associate with
intercellular junctions (Balda and Matter, 2000).
Y-box transcription factors are multifunctional regulators
of gene expression and have been proposed to play a general
role in promoting proliferation (Bargou et al., 1997; Matsu-
moto and Wolffe, 1998). Interestingly, low density epithe-
lial cells grow as islands of cells that are forming intercellular
junctions while they are still proliferating. Cell cycle arrest is
consequently not triggered by simple cell–cell contact, but
when monolayers reach a critical cell density. Nuclear
ZONAB levels are high in proliferating cells in peripheral
regions of growing islands that have still a low cell density;
but in central regions of islands where the cell density is
high, nuclear ZONAB levels are low (Balda and Matter,
2000). Here, we present data indicating that this differential
distribution of ZONAB reflects a role in the regulation of
epithelial proliferation and cell density. Our results show
that inhibition of ZONAB function by partial depletion of
total cellular pools or by increased expression of ZO-1 in-
hibits Go/G1 to S-phase transition and suggest that reduced
proliferation is at least in part due to an inhibition of the
CDK4/retinoblastoma protein pathway.
 
Results
 
Regulation of epithelial proliferation by ZONAB
 
ZONAB expression is high in proliferating but low in
growth-arrested MDCK cells (Fig. 1 A), suggesting that
high expression levels might be required for cell proliferation
(Balda and Matter, 2000). To test this, we used an antisense
RNA approach to reduce ZONAB expression. Stable expres-
sion of ZONAB antisense RNA resulted in a reduction of
cellular ZONAB levels by about 
 
 
 
50% (Fig. 1 B), whereas
expression of a 50% homologous Y-box factor, YB-1, was
not affected (unpublished data).
Next, we assessed proliferation by measuring [
 
3
 
H]thymidine
incorporation in low density cultures. Fig. 1 C shows that ex-
pression of ZONAB antisense RNA resulted in a fourfold re-
duction of [
 
3
 
H]thymidine incorporation, indicating that high
levels of ZONAB are indeed required for efficient prolifera-
tion. Further increases in ZONAB expression levels by overex-
pression of either ZONAB-A or ZONAB-B did not result in
increased incorporation of [
 
3
 
H]thymidine, suggesting that the
endogenous expression levels are sufficient for efficient prolif-
eration (Fig. 1, C and D). These data indicate that ZONAB
participates in the regulation of epithelial proliferation.
ZONAB localizes to the nucleus as well as tight junctions
in proliferating cells, but is not detectable in the nucleus of
nonproliferating high density cells (Balda and Matter,
2000), suggesting that accumulation of ZONAB in the nu-
cleus may be required for efficient proliferation. ZO-1 levels
are low in proliferating cells and increase with cell density,
and overexpression of ZO-1 inhibits the nuclear accumula-
tion of ZONAB (Balda and Matter, 2000); hence, ZO-1
may regulate proliferation by preventing ZONAB from ac-
cumulating in the nucleus. To test whether high levels of
ZO-1 expression reduce proliferation, we used cell lines in
which ZO-1 was three- to fivefold overexpressed in low con-
fluent cells; an increase that is comparable to the up-regula-
tion of the protein in wild-type cells once they reach high
cell densities (Fig. 2, A and B). Next, we assessed prolifera-
tion by measuring [
 
3
 
H]thymidine incorporation in low den-
sity cultures. Fig. 2 C shows that exogenous expression of
ZO-1 resulted in a fourfold reduction of [
 
3
 
H]thymidine in-
corporation, indicating that high levels of ZO-1 expression
indeed reduced proliferation.
ZO-1 interacts with ZONAB via its SH3 domain (Balda
and Matter, 2000); hence, if ZO-1 inhibits proliferation via
ZONAB, the antiproliferative effect of ZO-1 should de-
pend on its SH3 domain. To determine whether the
Figure 1. Regulation of proliferation by ZONAB. (A) MDCK cells 
were grown for the indicated amounts of days. Cultures were 
harvested and equal amounts of protein were loaded on SDS-PAGE 
gels for analysis of ZONAB expression by immunoblotting. The 
bands representing the ZONAB-A and -B isoforms are indicated. 
Parallel cultures were trypsinized, and the cells were counted to 
determine the cell density. (B) Reduction of ZONAB expression in 
low density cells by ZONAB antisense RNA. Proliferating wild-type 
MDCK cells (wt MDCK) and cells expressing ZONAB antisense 
RNA (ZONABas) were harvested, and equal amounts of protein 
were loaded on SDS-PAGE gels for analysis of ZONAB expression 
by immunoblotting. Based on densitometric scanning of the 
immunoblots, expression of ZONAB was reduced by  50% in cells 
transfected with the antisense construct. (C) Proliferation of low 
density MDCK cells expressing ZONAB antisense RNA (ZONABas), 
a control missense RNA (msRNA), overexpressing either one of the 
ZONAB isoforms, or transfected with a control cDNA were analyzed 
by measuring incorporation of [
3H]thymidine. Data were normalized 
to wild-type cells (shown are means   1 SD of at least three 
independent clones per construct that were analyzed in three 
independent experiments with quadruplicate cultures). Note that 
incorporation of [
3H]thymidine by ZONABas cells was reduced by 
 70% (t test; P   0.01). (D) Overexpression of ZONAB isoforms 
in low density MDCK cells. Proliferating wild-type MDCK cells 
(wt MDCK) and cells overexpressing ZONAB-A or ZONAB-B were 
harvested, and equal amounts of protein were loaded on SDS-PAGE 
gels for analysis of ZONAB expression by immunoblotting.T
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ZONAB binding site of ZO-1 is needed for the regula-
tion of proliferation, we generated MDCK cells expressing
HA-tagged full-length or truncated ZO-1 and measured
[
 
3
 
H]thymidine incorporation in low density cultures. Fig. 2
C shows that HA-ZO-1 inhibited [
 
3
 
H]thymidine incorpo-
ration, indicating that the epitope did not interfere with
ZO-1’s role in proliferation control. Overexpression of
ZO-1 lacking the SH3 domain, however, did not affect
[
 
3
 
H]thymidine incorporation even though these cell lines
expressed similar amounts of transfected protein (unpub-
lished data). The SH3 domain is thus critical for ZO-1 to
control proliferation. None of the other domains of ZO-1
was found to be required for inhibiting [
 
3
 
H]thymidine in-
corporation (Fig. 2, C and D).
If the overexpression of ZO-1 indeed reduces proliferation
due to sequestration of ZONAB, one would expect that co-
expression of ZONAB neutralizes the effect of ZO-1. Fig. 2
C shows that the inhibitory effect of ZO-1 was indeed neu-
tralized by coexpression of ZONAB-A, supporting the con-
clusion that ZO-1 regulates proliferation by interacting with
ZONAB.
Y-box transcription factors have been proposed to regulate
cell cycle entry (Bargou et al., 1997; Matsumoto and
Wolffe, 1998), and ZONAB cannot be detected in the nu-
cleus in nonproliferating high density cells. To test whether
ZONAB regulates cell cycle entry, we synchronized low
density cultures of MDCK cells in Go/G1 phase by serum
starvation. Based on FACS analysis, around 75% of the cells
were arrested in Go/G1 after the 48-h incubation in 0.1%
serum (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200210020/DC1). Entry into S-phase on addition
of serum was then quantified by determining the incorpora-
tion of [
 
3
 
H]thymidine. Fig. 3 A shows that ZO-1 overex-
pression indeed reduced DNA synthesis, suggesting that en-
try into S-phase was affected. The ZO-1 effect depended on
the presence of the SH3 domain, and overexpression of
ZONAB again reversed the levels of [
 
3
 
H]thymidine incorpo-
ration to control levels. This suggests that ZO-1 indeed reg-
ulates cell cycle entry.
To confirm the [
 
3
 
H]thymidine data and to determine the
number of cells that actually entered S-phase, we counted
the cells incorporating BrdU. Fig. 3 B shows that exogenous
expression of ZO-1 resulted in reduced numbers of cells en-
tering S-phase, and that coexpression of ZONAB again
counteracted the inhibition by ZO-1. Reduced proliferation
was not found to be paralleled by increased rates of apoptosis
or senescence (Fig. S1). These data suggest that overexpres-
sion of ZO-1 regulates entry into S-phase.
Next, we wanted to test whether reduction of total cellular
ZONAB levels also inhibits cell cycle entry. Because expres-
sion of long antisense RNAs as the one used in the experi-
ment described in Fig. 1 can cause nonspecific cellular re-
sponses due to activation of antiviral defense mechanisms
(Williams, 1999), we used an alternative approach to reduce
ZONAB expression. This second approach was based on the
expression of small ZONAB-directed RNA duplexes to in-
Figure 2. Regulation of proliferation by ZO-1. (A and B) Expression 
of ZO-1 in wild-type and transfected MDCK cells. Wild-type MDCK 
cells (A) or wild-type (wt MDCK) and ZO-1–overexpressing (ZO-1 1/21 
and ZO-1 2/3) cells (B) were grown for the indicated number of 
days as described in Fig. 1 A. Cells were then harvested, and equal 
amounts of protein were loaded on SDS-PAGE gels for analysis 
of ZO-1 expression by immunoblotting. Note that ZO-1 was 
overexpressed in transfected proliferating cells to a similar extent as 
it was up-regulated in mature monolayers. (C) Incorporation of 
[
3H]thymidine by low density MDCK cells stably transfected with 
ZO-1 or HA-tagged ZO-1 with (HA-ZO-1) or without (HA-ZO-1 SH3) 
the SH3 domain, or constructs containing specified domains. 
ZO-1/ZONAB indicates data obtained from double transfected cells 
overexpressing both proteins. Data were normalized to wild-type 
cells (shown are means   1 SD of at least three independent clones 
per construct that were analyzed in three independent experiments 
with quadruplicate cultures). Note that all cell lines expressing 
constructs containing the SH3 domain of ZO-1 exhibited significantly 
reduced [
3H]thymidine incorporation (t test; P   0.05). (D) Domain 
structure of ZO-1. PDZ, PSD95-DlgA-ZO-1 homology domain; SH3, 
src homology domain 3; GUK, guanylate kinase homology domain.
Figure 3. Regulation of G1/S-phase transition by ZO-1 and 
ZONAB. Wild-type (wt MDCK) and transfected MDCK cells 
expressing the indicated cDNAs were plated at low confluence and 
then synchronized in low serum. Cell cycle entry was then triggered 
by serum addition, and progression to S-phase was monitored by 
measuring incorporation of [
3H]thymidine (A) or BrdU (B). Note, 
whereas in A total DNA synthesis was measured, B shows the fraction 
of cells in S-phase. Expression of full-length ZO-1 significantly 
inhibited entry into S-phase (t test; A, P   0.05; B, P   0.01). Shown 
are means   1 SD of three independent clones per construct that 
were analyzed in at least three different experiments performed in 
quadruplicate.T
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duce RNA interference using a recently described expression
vector containing an RNA polymerase III promoter (Yu et
al., 2002). Fig. 4 A shows that stable transfection of two dif-
ferent vectors targeting different regions of the ZONAB se-
quence resulted in efficient reduction of ZONAB expres-
sion, but a vector expressing a control RNA duplex with a
random sequence did not affect ZONAB expression.
Next, we used these cell lines to determine whether re-
duced ZONAB expression affects cell cycle entry. Cells were
arrested in Go/G1 and cell cycle entry was stimulated by the
addition of serum. Fig. 4 B shows that reduction of ZONAB
expression by RNA interference reduced the number of cells
that had entered S-phase after serum stimulation by 
 
 
 
50%.
Entry into S-phase of clones expressing control RNAs was
not affected. These data support the conclusion that high lev-
els of ZONAB expression are required for efficient prolifera-
tion, and suggest that ZONAB participates in the regulation
of Go/G1–S-phase transition.
 
Regulation of cell density by ZONAB
 
Because reduced nuclear expression of ZONAB in low den-
sity cells reduces proliferation and ZONAB becomes down-
regulated with increasing cell density (Fig. 1 A; Balda and
Matter, 2000), we used cell lines overexpressing either one
of the ZONAB isoforms to test whether overexpression of
ZONAB affects either cell cycle arrest in high density cells or
the final cell density (Fig. 5 A). First, we labeled high density
cells with BrdU to determine whether overexpression of
ZONAB affects cell cycle arrest in mature monolayers.
Quantification of BrdU-positive cells revealed that only a
small percentage of ZONAB-overexpressing cells still synthe-
sized DNA comparable to nontransfected cells or cell lines
overexpressing ZO-1 (Fig. 5 B). Thus, ZONAB overexpres-
sion did not cause continued proliferation of high density
Figure 5. Regulation of final cell density by ZONAB. (A) Expression 
of ZONAB in high density wild-type and transfected MDCK cells. 
Wild-type (wt MDCK) and ZONAB-A or -B overexpressing cells 
were grown for 7 d. Cells cultured for 7 d had reached maximal cell 
density. Cultures were harvested, and equal amounts of protein 
were loaded on SDS-PAGE gels for analysis of ZONAB expression 
by immunoblotting. (B) Cell cycle arrest of high density MDCK cells. 
Wild-type or transfected MDCK cells overexpressing ZO-1 or ZONAB 
were grown to full density, and cell cycle arrest was determined by 
BrdU incorporation. Shown are representative images of propidium 
iodide and BrdU labelings, and the indicated numbers are the 
percentage of BrdU-positive cells (averages of two independent 
experiments are shown). Note the different cell densities in the 
propidium iodide staining. (C) Cell density of mature monolayers. 
Cells grown as those in B were harvested and counted. The cell 
number per cm
2 of culture was calculated and expressed as percent 
changes relative to wild-type MDCK cells. The value shown for 
control transfections (control T) represents cell densities obtained 
from cell lines expressing three different control cDNAs generated 
with the same expression vector. Shown are averages   1 SD of 
independent clones that were analyzed twice independently using 
triplicate cultures. Analyzed were three different clones expressing 
ZONAB-A, three ZONAB-RD-I clones, and two independent clones 
each for ZONAB-B, ZO-1, ZONAB-RD-II, and Control-RD. All cell 
lines with the exception of the two types of control transfection were 
significantly different from wild-type cells (t test; P   0.05).
Figure 4. Depletion of ZONAB by RNA interference inhibits 
G1/S-phase transition. (A) Wild-type MDCK cells or cells stably 
expressing RNA duplexes corresponding to region I (ZONAB-RD-I 
c1 and c2) or II (ZONAB-RD-II c8 and c9) of ZONAB, or control 
RNA duplexes (control-RD c1 and c3) were grown for 2 d and 
then lysed and processed for electrophoresis. The samples were 
immunoblotted with anti-ZONAB and anti– -tubulin antibodies. 
(B) Wild-type and transfected MDCK cells expressing the indicated 
RNA duplexes were plated at low confluence and synchronized in 
low serum. Cell cycle entry was triggered by serum addition, and 
progression to S-phase was monitored by determining the fraction 
of cell incorporation of BrdU. Shown are means   1 SD of at least 
two independent clones per type of RNA duplex that were analyzed 
in two independent experiments. Both ZONAB-directed RNA duplexes 
significantly inhibited entry into S-phase (t test; P   0.02).T
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MDCK cells. However, visualization of nuclei with propidium
iodide suggested that cells reached different final cell densities.
Next, we quantified the cell density of mature monolayers
that were grown as those in Fig. 5 B. These experiments re-
vealed that cells expressing exogenous ZONAB grew to cell
densities that were 
 
 
 
40% higher than the density reached
by wild-type cells. Overexpression of ZO-1 consequently
produced monolayers with a decreased final cell density sim-
ilar to the reduction of ZONAB expression levels by RNA
interference. These results suggest that ZONAB and ZO-1
regulate the cell density at which cell cycle arrest occurs dur-
ing monolayer formation.
 
Interaction of ZONAB and CDK4
 
The human Y-box factor DbpA has been shown to inter-
act in a two-hybrid screen as well as in vitro with cell di-
vision kinases (CDKs), suggesting that Y-box factors may
regulate the activity or subcellular localization of CDKs
(Moorthamer et al., 1999). This interaction involves a do-
main that is highly conserved in all Y-box factors and that is
also thought to participate in DNA binding and regulation
of transcription. We hypothesized that ZONAB also inter-
acts with a CDK and, hence, may affect proliferation by in-
fluencing either the activity or subcellular localization of a
CDK involved in the regulation of entry into S-phase.
First, we immunoprecipitated extracts generated from
wild-type MDCK cells with a stringent buffer (i.e., contain-
ing deoxylcholate, SDS, Empigen BB, and Triton X-100),
and monitored the presence of CDKs by immunoblotting
using a 
 
 
 
-chain–specific secondary antibody. Under strin-
gent extraction conditions, CDK4 was present in immuno-
precipitates generated with anti-ZONAB antibodies, but ab-
sent from control precipitates (Fig. 6 A). Other tested CDKs
(e.g., CDK6) were not detected in ZONAB precipitates
(unpublished data).
To determine whether ZONAB-associated CDK4 is com-
plexed to cyclin D1, we used more gentle conditions to ex-
tract the cells (i.e., 1% Triton X-100 in PBS) that do not
break the interaction between the cyclin and the CDK. Both
CDK4 and cyclin D1 could be detected in ZONAB immu-
noprecipitates generated from such extracts, suggesting that
at least part of the ZONAB-bound CDK4 is complexed to
cyclin D1 (Fig. 6 B). The interaction between ZONAB and
CDK4 could be reconstituted with recombinant proteins,
indicating that this is indeed a direct interaction (Fig. 6 C).
CDK4 is a key regulator of G1/S transition (Sherr, 2000;
Malumbres and Barbacid, 2001). Hence, ZONAB could
regulate proliferation by controlling the activity or the local-
ization of CDK4. To test whether ZONAB influences the
kinase activity of CDK4, we measured the activity of recom-
binant CDK4/cyclin D1 using GST-retinoblastoma as a
substrate in the absence or presence of purified GST-
ZONAB (Fry et al., 2001). Fig. 6 D shows that in vitro
CDK4 activity was not significantly affected by ZONAB,
suggesting that ZONAB does not affect the activity of
CDK4. This is also supported by the finding that ZONAB
immunoprecipitates were found to contain an active kinase
activity that phosphorylates recombinant retinoblastoma
protein (unpublished data).
Figure 6. Interaction of ZONAB with CDK4. MDCK cells were 
extracted under stringent conditions (A) or in PBS-Triton X-100 (B), 
and cell extracts were subjected to immunoprecipitation with the 
indicated antibodies. CDK4 and cyclin D1 were then detected by 
immunoblotting using a  -chain–specific secondary antibody. (C) In 
vitro interaction between recombinant His-tagged ZONAB and 
GST-tagged CDK4. Glutathione beads loaded with either GST or 
GST-CDK4 were incubated with His-tagged ZONAB fusion protein. 
The beads were then washed, and pull-down was monitored by 
immunoblotting. A His-tagged control fusion protein was not 
detected in the precipitates (not depicted). (D) Kinase activity of 
recombinant CDK4/cyclin D1 was assayed in the presence of 
recombinant GST-ZONAB or GST using GST-retinoblastoma 
(GST-Rb) as a substrate. Note that CDK4 activity was not affected 
by GST-ZONAB.
Figure 7. Association of CDK4 with intercellular junctions. 
(A and B) MDCK cells were plated on coverslips and grown for 3 d. 
The cells were then fixed with methanol and processed for double 
immunofluorescence using rabbit anti-CDK4 and rat anti–ZO-1 
antibodies. Shown are confocal XY-sections (A, CDK4; B, ZO-1 
staining). (C and D) Confocal XY-sections of MDCK cells transiently 
transfected with a cDNA coding for HA-tagged CDK4. The cells 
were stained with rabbit anti-HA and rat anti–ZO-1 antibodies 
(C, HA-CDK4; D, ZO-1 staining). Bars, 10  m.T
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Because CDK4 was found to coimmunoprecipitate with
ZONAB, one would expect that the two proteins have a
similar subcellular distribution. To test this, proliferating
MDCK cells, in which ZONAB localizes to the nucleus as
well as tight junctins, were fixed and processed for immu-
nofluorescence using an antibody against CDK4. Fig. 7 A
shows that endogenous CDK4 was indeed detected in the
nucleus as well as at cell–cell junctions, which were visual-
ized with anti-ZO-1 antibodies (Fig. 7 B). Similar stainings
were obtained with two different CDK4 antibodies. To test
CDK4 association with cell–cell junctions in an indepen-
dent manner, we transiently expressed HA-tagged CDK4 in
MDCK cells. Fig. 7 C shows that HA-CDK4 also localizes
to intercellular junctions that were labeled with anti-ZO-1
antibody (Fig. 7 D).
Overexpression of ZO-1 in low density cells causes a re-
distribution of ZONAB from the nucleus to the cytoplasm
(Balda and Matter, 2000) and, as shown in Fig. 2, reduced
proliferation. Because ZONAB binds CDK4, the nuclear
pools of the two proteins may decrease in parallel. To test
this, we isolated nuclear fractions from proliferating wild-
type and ZO-1–transfected cells and measured the amount
of nuclear ZONAB and CDK4. Fig. 8 A shows that the nu-
clear pools of CDK4 were strongly reduced by overexpres-
sion of ZO-1, as were ZONAB levels. Quantification of the
immunoblots revealed that the nuclear pools of both pro-
teins were reduced by 
 
 
 
60% compared with wild-type cells.
This effect was specific for CDK4 because the nuclear accu-
mulation of CDK6, a kinase that does not coprecipitate with
ZONAB, was not affected. This indicates that ZO-1 expres-
sion levels regulate the subcellular distribution of CDK4.
This is also supported by the observation that in high den-
sity MDCK cells, which express high levels of ZO-1, CDK4
is primarily cytoplasmic (unpublished data).
If the redistribution of CDK4 in ZO-1 overexpressing
cells is ZONAB-dependent and causes the reduction of pro-
liferation, one would expect that expression of the SH3 do-
main of ZO-1 is sufficient to induce the redistribution of
ZONAB and CDK4 observed in ZO-1 overexpressing cells.
Fig. 8 B shows that the nuclear levels of ZONAB and
CDK4 in MDCK cells expressing HA-SH3 were reduced to
a similar extent as in ZO-1–overexpressing cells (see Fig. 8 C
for quantification). Moreover, reduction of the cellular
ZONAB level by expression of ZONAB antisense RNA re-
 
and the ratio of nuclear versus total signal was calculated. For each 
experiment, the ratio obtained from wild-type cells was set to 1 and the 
other cell lines were normalized to this value. Shown are averages 
 
 
 
1 SD from at least three independent experiments. The values 
obtained for ZONAB, CDK4, and cyclin D1 in ZO-1, HA-SH3, and 
ZONABas cells were significantly different from those of wild-type 
cells with a confidence level of P 
 
  
 
0.02. (D) Reduced cell density in 
cells expressing a CDK4 inhibitor. Wild-type and transfected MDCK 
cells were grown as in Fig. 5 C, and were then harvested and 
counted. The cell number per cm
 
2
 
 of culture was calculated and 
expressed as percent changes relative to wild-type MDCK cells. Two 
independent clones expressing VSV-tagged p16-INK4a were analyzed 
in two independent experiments performed in triplicate. For 
comparison, the values of ZONAB-overexpressing or depleted clones 
from Fig. 5 are also shown. Note that expression of p16-INK4a 
significantly reduced the final cell density (
 
t
 
 test; P 
 
  
 
0.05).
Figure 8.
 
Regulation of CDK4 accumulation in the nucleus
 
. 
(A) Nuclear fractions isolated from low density wild-type and ZO-1–
overexpressing MDCK cells were immunoblotted for the indicated 
proteins. Equal amounts of protein were loaded for all homogenates 
and for all nuclear fractions. The weak upper band in the CDK4 blot 
is a background band that was only detected by early batches of the 
commercial anti-CDK4 antibody, but not by later ones (see panel B 
for comparison). (B) Wild-type cells, clones transfected with cDNAs 
for either ZO-1 or the HA-tagged SH3 (HASH3), or cells expressing 
antisense ZONAB RNA (ZONABas) were grown, franctionated, and 
analyzed as in the experiment shown in A. To increase the sensitivity 
and accuracy of quantification, higher amounts of nuclear protein 
were loaded in B as compared with A to obtain bands with a similar 
intensity. (C) Quantification of nuclear accumulation. Immunoblots 
such as those shown in B were quantified by densitometric scanning, T
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sulted in strongly reduced nuclear ZONAB levels. A smaller
proportion of the remaining ZONAB was nuclear than in
wild-type cells, suggesting that the expression level of
ZONAB determines its relative distribution. Consequently,
this was paralleled by a reduction in the nuclear pool of
CDK4, indicating that high levels of ZONAB are required
for efficient accumulation of CDK4 in the nucleus. In all
cases, the reduction of CDK4 was paralleled by a reduction
of nuclear cyclin D1, the main cyclin binding CDK4. These
observations suggest that inhibition of the nuclear accumu-
lation of ZONAB results in less nuclear CDK4 activity. This
is supported by the observation that such cell lines exhibited
reduced hyperphosphorylation of retinoblastoma protein, a
nuclear CDK substrate (unpublished data).
Reduced expression of ZONAB and overexpression of
ZO-1 were shown to decrease the final cell density of
MDCK monolayers (Fig. 5). If this effect is at least in part
due to reduced CDK4 function, one would expect that inhi-
bition of CDK4 by other means would also affect the final
cell density; hence, we generated MDCK cells overexpress-
ing the CDK4 inhibitor p16INK4a tagged with a COOH-
terminal VSV epitope (p16-VSV). Fig. 8 D shows that
monolayers expressing p16-VSV also stopped growing at
lower cell densities similar to ZO-1–overexpressing cells,
suggesting that regulation of CDK4 is sufficient to modulate
the cell density of mature epithelial monolayers.
 
Discussion
 
Our results indicate that ZONAB functions in the regula-
tion of epithelial proliferation and cell density. Reduction of
ZONAB expression levels were found to reduce prolifera-
tion rates and final cell densities, whereas overexpression re-
sulted in monolayers with increased cell densities. Premature
increases in expression of ZO-1 in low density cells, which
results in decreased nuclear ZONAB levels, also resulted in
reduced proliferation and, in mature monolayers, decreased
cell density. These observations suggest that ZONAB and
ZO-1 are part of a pathway by which tight junctions can
regulate epithelial cell proliferation and density.
ZONAB was found to interact with CDK4, and manipula-
tions that resulted in lowered nuclear pools of ZONAB also
decreased nuclear CDK4 levels and reduced hyperphosphory-
lation of retinoblastoma protein. These data suggest that regu-
lation of the nuclear accumulation of CDK4 represents one
way by which ZONAB and ZO-1 can influence epithelial pro-
liferation. Increased ZO-1 and decreased ZONAB expression
not only resulted in reduced proliferation, but also in lowered
cell densities in mature monolayers, and overexpression of
ZONAB had the opposite effect on cell density. Interestingly,
experiments in mice linked CDK4 to the regulation of cell
number in certain tissues (Malumbres and Barbacid, 2001),
suggesting that regulation of CDK4 function by ZONAB and
ZO-1 may be important for the regulation of cell density. This
possibility is further supported by the observation that inhibi-
tion of CDK4 by expression p16INK4a was sufficient to re-
duce cell density in mature MDCK monolayers.
CDK4 is a central regulator of cellular proliferation, and
its activity is tightly controlled by several interacting proteins
(Serrano, 1997; Ekholm and Reed, 2000; Sherr, 2000;
Malumbres and Barbacid, 2001). Generally, these proteins
either activate or inhibit the kinase. Inhibitory proteins can
be transcription factors that are up-regulated during termi-
nal differentiation (Zhang et al., 1999; Wang et al., 2001).
The here-described mechanism of regulating CDK4 is dif-
ferent in two aspects. First, ZONAB does not directly affect
the enzymatic activity of CDK4, but links it to a mechanism
that controls the nuclear accumulation of the kinase. Sec-
ond, ZONAB is up-regulated during proliferation and
down-regulated in differentiated cells, resulting in nuclear
accumulation at times of high nuclear CDK4 activity.
ZONAB is a transcription factor and may therefore not
only control proliferation by regulating CDK4 localization,
but also by modulating the expression of genes coding for
proteins involved in proliferation. Y-box transcription fac-
tors bind to inverted CCAAT boxes, which occur frequently
in promoters of cell cycle regulators (Ladomery and Som-
merville, 1995; Bargou et al., 1997; Chen, 1997), and
ZONAB can bind to some of them in gel shift assays (Balda
and Matter, 2000). Direct evidence for ZONAB function-
ing in the suppression or activation of promoters of cell cycle
regulators has not yet been obtained, however, and will re-
quire a comprehensive search for ZONAB target genes. The
only currently known gene that is regulated by ZONAB is
erbB-2 (Balda and Matter, 2000). However, neither overex-
pression nor down-regulation of ErbB-2 with a KDEL-
tagged single chain antibody affected the proliferation rates
of MDCK cells (unpublished data), indicating that regula-
tion of ErbB-2 expression is not part of the mechanism by
which ZONAB regulates proliferation of these cells. Never-
theless, it is attractive to speculate that ZONAB forms a
complex with CDK4, and that nuclear accumulation of the
two proteins is co-regulated because they both have nuclear
functions that are critical for proliferation.
ZONAB function can be regulated by at least two differ-
ent mechanisms; the overall expression level and the subcel-
lular distribution. ZONAB is expressed at high levels in pro-
liferating cells and at low levels in confluent cells (Balda and
Matter, 2000); the mechanisms that control up-regulation
and down-regulation are not known yet, but may involve
potential PEST sequences residing in the COOH-terminal
half of the protein.
The subcellular distribution of ZONAB is regulated by
the expression level of ZO-1 and the cell density (Balda and
Matter, 2000). If ZO-1 is overexpressed in low confluent
cells or monolayers reach full cell density, the nuclear
ZONAB pools and proliferation are reduced. ZO-1 levels
increase with cell density and become down-regulated when
proliferation is required (e.g., during wound repair), suggest-
ing that up-regulation of ZO-1 contributes to cell cycle ar-
rest in mature monolayers. It will be important to determine
how expression of ZO-1 is regulated. Because the half-life of
ZO-1 has been demonstrated to increase with cell density,
stabilization of the protein at forming intercellular junctions
appears to be important for the up-regulation (Gumbiner et
al., 1991). Nevertheless, it is likely that the contribution of
transcriptional mechanisms is also important for the regula-
tion of ZO-1 expression. This is suggested by the observa-
tion that ZO-1 mRNA is down-regulated during corneal
wound repair (Cao et al., 2002).T
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The interaction of ZO-1 with tight junctions may only be
important for the stabilization of ZO-1, but not to anchor
ZO-1 to the plasma membrane to inhibit nuclear accumula-
tion of associated proteins. This is suggested by the observa-
tion that a truncated protein consisting only of the HA-
tagged SH3 domain accumulated in the cytosol (unpublished
data), but was sufficient to reduce proliferation and nuclear
accumulation of ZONAB. Hence, binding of the SH3 do-
main to ZONAB may compete with another interaction re-
quired for nuclear transport by, for example, restricting access
to a nuclear localization signal. Because reduction of cellular
ZONAB levels resulted in reduced nuclear accumulation of
CDK4, it is possible that ZONAB plays a role in nuclear
transport of CDK4. Alternatively, the reduced but preferen-
tially cytoplasmic pool of ZONAB may have been sufficient
to retain a large proportion of CDK4 in the cytoplasm.
Our data indicate that ZONAB and ZO-1 regulate prolif-
eration and the final cell density of MDCK cells. The obser-
vations that ZO-1 accumulates with increasing cell density,
and increased expression of ZO-1 in transfected cells reduces
the final cell density suggest a model in which ZO-1 func-
tions as a gauge for cell density that, on reaching a threshold
level, signals growth arrest by cytoplasmic sequestration of
ZONAB and the associated cell cycle kinase CDK4. Conse-
quently, reduction of ZONAB expression also reduced cell
density, whereas overexpression resulted in monolayers with
more cells.
Multiple signaling pathways regulate epithelial prolifera-
tion and can become activated if epithelial sheets are dis-
turbed and intercellular junctions are disrupted (Behrens,
1999; Li and Mrsny, 2000; Reichert et al., 2000; Ryeom et
al., 2000; Gottardi and Gumbiner, 2001; Savagner, 2001;
Vietor et al., 2001). Overexpression of ZONAB resulted in
increased cell density, but did not cause overgrowth of
MDCK cells, suggesting that ZONAB becomes either inacti-
vated or overridden by other signaling pathways. Such mech-
anisms may be cell type-dependent as ZONAB overexpres-
sion accelerates proliferation of a mammary epithelial cell line
(unpublished data). It will be crucial to determine how the
ZO-1/ZONAB pathway cross talks with other signaling sys-
tems that influence proliferation. For example, 
 
 
 
-catenin as
well as ECM signaling regulate the expression of cyclin D1,
which activates CDK4 (Zhao et al., 1998; Shtutman et al.,
1999; Tetsu and McCormick, 1999; D’Amico et al., 2000;
Assoian and Schwartz, 2001). Thus, it is striking that multi-
ple pathways deriving from structures mediating cell adhe-
sion can regulate cell cycle progression via regulation of
CDK4, and it will be important to determine how these dif-
ferent pathways interact with each other during epithelial dif-
ferentiation and development.
 
Materials and methods
 
Cell lines and cDNAs
 
MDCK cells overexpressing ZO-1 and ZONAB isoforms were generated
with the CMV-based expression vector pCB6 and were described previ-
ously (Balda and Matter, 2000). Cells expressing epitope-tagged ZO-1 con-
structs and ZONAB antisense RNA were generated using the bicistronic
CMV-based pCIN4 expression vector (Rees et al., 1996). p16-INK4a was
tagged with a COOH-terminal VSV epitope and cloned into pCB6 for sta-
ble expression.
The mU6pro vector was used for the expression of RNA duplexes (Yu et
al., 2002). Two regions of ZONAB were targeted that are part of the se-
quence coding for different protein domains (region I, 5
 
 
 
-AAGTTCTCGC-
CACCAAAGTCC-3
 
 
 
; region II, 5
 
 
 
 AACTTACCGCCCAAGGTACCG-3
 
 
 
).
Derivatives of the mU6pro vector were constructed as described previ-
ously (Yu et al., 2002), and were cotransfected with a plasmid carrying a
puromycin resistance gene for the selection of stable cell lines. All func-
tional assays with transfected cells were performed with 2–5 independent
clones for each construct.
A cDNA coding for CDK4 was generated by RT-PCR from total RNA
isolated from Caco-2 cells and cloned into the pCB6 expression vector
containing an HA-tag (Balda et al., 1996). The resulting plasmid pCB6-HA-
CDK4 was transfected into MDCK cells by calcium phosphate and expres-
sion was analyzed after 48 h.
 
Antibodies
 
Rabbit anti-CDK4, goat anti-CDK6, and anti-retinoblastoma antibodies
were obtained from Santa Cruz Biotechnology, Inc., and the rabbit anti-
cyclin D1 antibody was purchased from MBL International Corporation.
An additional anti-CDK4 antibody was generated against a peptide with
the sequence NH
 
2
 
–A F R A L Q H S Y L H K D E–COOH and was affinity-
purified using the same peptide coupled to sepharose beads. The peptide
NH
 
2
 
–S S E A E T Q Q P P A A P P–COOH was used to generate a rabbit
anti-YB1 antibody. All other antibodies were as described previously
(Balda and Matter, 2000). For 
 
 
 
-tubulin, mAb 1A2 was used (Kreis, 1987).
 
Biochemical assays and immunofluorescence
 
Cells were solubilized in either 10 mM Hepes, pH 7.4, 150 mM NaCl, 1%
Empigen BB, 1% Triton X-100, 0.5% sodium deoxylcholate, and 0.2% so-
dium dodecylsulfate for stringent immunoprecipitates, or in PBS contain-
ing 1% Triton X-100 for less stringent conditions. Both extraction buffers
contained protease and phosphatase inhibitor cocktails. ZO-1 and
ZONAB were then immunoprecipitated as described previously (Balda
and Matter, 2000). Recombinant His-tagged ZONAB, GST-tagged CDK4,
and GST were produced in 
 
Escherichia coli
 
, and interaction between the
proteins was tested in PBS containing 0.5% Triton X-100 (Balda and Mat-
ter, 2000). GST and GST-CDK4 were pulled down using glutathione-aga-
rose, and His-ZONAB was visualized by immunoblotting with an antibody
specific for the COOH terminus of ZONAB. Enzymatic assays for CDK4
were performed as described previously (Fry et al., 2001). Nuclear frac-
tions were isolated essentially as described previously (Balda and Matter,
2000), except that the centrifugation step was performed with an S80AT3
rotor in an ultracentrifuge (40,000 rpm for 50 min; model RC M150, Sor-
vall). Equal amounts of proteins of all homogenates and equal amounts of
proteins of all nuclear fractions were loaded on SDS-PAGE gels, and the
presence of particular proteins was tested by immunoblotting. For immu-
nofluorescence, cells were plated on glass coverslips and cultured for at
least 3 d. Processing for immunofluorescence and confocal microscopy
was performed as described previously (Balda and Matter, 2000).
 
Analysis of proliferation and cell density
 
Confluent cells were trypsinized and plated (5,600 cells/cm2) in 10% FCS
for 2 d. At such an early stage of proliferation, all cultures were still at a
low density and formed only small islands of cells that, based on BrdU la-
belings, did not yet have a significant proportion of arrested cells in their
center. 24-well plates were used for all experiments, and all determina-
tions were done in quadruplicate. For synchronized cultures, the cells
were washed with PBS and transferred to 0.1% of serum for 2 d. For
[
 
3
 
H]thymidine incorporation, the cells were then incubated for 24 h with
0.1 or 10% serum-containing medium including 1
 
  
 
Ci/ml [
 
3
 
H]thymidine
and 0.24 
 
 
 
g/ml thymidine. The incorporation was stopped with two
washes with cold PBS, precipitation with 5% TCA, and two washes with
cold ethanol. The samples were solubilized with SDS in sodium carbonate
and counted. For BrdU incorporation, the cells were incubated with 100
 
 
 
M BrdU for the last 2 h of the incubation with 10% serum. The cells were
washed with PBS, fixed with methanol for 10 min at 4
 
 
 
C, washed with
PBS, and incubated with 1.5 M HCl for 30 min at RT. After four washes
with threefold PBS (5–10 min each) and blocking with 1% BSA, the cells
were incubated with mouse anti-BrdU with nuclease (Amersham Bio-
sciences). After 2 h, the samples were washed and were stained with a flu-
orescently labeled goat anti–mouse antibody and Hoechst 33258 or pro-
pidium iodide. For quantification, pictures of 4–6 different fields were
taken and counted (400–500 cells per sample).
For the flow cytometric analysis, MDCK cells were washed with PBS/
EDTA, trypsinized, washed with cold PBS, and counted. 2 
 
 
 
 10
 
6
 
 cells re-
suspended in 300 
 
 
 
l PBS were then slowly added to 700 
 
 
 
l of 
 
 
 
20
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anol (on a vortex at low speed) and were subsequently left at 4
 
 
 
C for 2 h
(Urbani et al., 1995). The mix was vortexed four times during this incuba-
tion. After washing twice with cold PBS, the cells were incubated with 400
 
 
 
l of 1% Triton X-100 in PBS containing 0.2 mg/ml RNase A (DNase free)
and 20 ug/ml propidium iodide for 2 h at 37
 
 
 
C. During this time, the cells
were resuspend every 20–30 min by vortexing. Flow cytometric analysis
was performed on a Becton Dickinson flow cytometer (University Medical
Center, University of Geneva, Geneva, Switzerland).
Apoptosis was determined by fluorescent detection of active caspase-3
using the CaspACE™ FITC-VAD-FMK in situ marker (Promega). In brief,
cells were incubated for 20 min with the marker, washed twice with PBS,
fixed, mounted, and observed with a fluorescence microscope. Senes-
cence-associated 
 
 
 
-galactosidase staining was performed at pH 6.0 for se-
nescence-associated activity, at pH 4.0 for lysosomal (positive control),
and at pH 7.5 for bacterial 
 
 
 
-galactosidase (negative control) essentially as
described previously (Dimri et al., 1995). Cells were washed in PBS, fixed
in 3% PFA (3–5 min at RT), washed, and incubated at 37
 
 
 
C with fresh sub-
strate solutions (1 mg/ml of 5-bromo-4-chloro-3-indolyl-b-
 
D
 
-galactoside in
corresponding buffer). Staining was evident within 2–4 h and maximal af-
ter 12–16 h. Before observation, the cells were rinsed twice with PBS and
washed with methanol.
For cell density experiments, the cells were grown to high cell densities
(controlled by visual inspection) in 12-well plates and were then cultured
for seven more days. After this time, the analyzed MDCK cell lines were
arrested and did not exhibit any differences in BrdU incorporation. The
cells were then trypsinized and subsequently resuspended, and counted
with a hematocytometer.
 
Online supplemental material
 
Results illustrating synchronization and viability of wild-type and trans-
fected MDCK cells can be found at http://www.jcb.org/cgi/content/full/
jcb.200210020/DC1.
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